

LUNG

LUNG DISEASE SITE COMMITTEE

AGENDA OPEN SESSION

Chelsea Hotel, Toronto, ON
Room: Churchill A
Saturday May 4, 2019, 1:30 – 4:00 pm EST

Chair: Penelope Bradbury
CCTG Senior Investigator: Joe Pater

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

CME Learning Objectives:

- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to the management of lung cancer
- To cite and analyze recent results of lung cancer clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group

1:30 – 1:45 pm	Welcome and Introduction	P. Bradbury
1:45 – 2:15 pm	Academic clinical trial group trials in the future - challenges and opportunities?	N. Pavlakis
2:15 – 2:40 pm	Rapid Fire Trial Chair Updates	
2:15 – 2:20 pm	BR.31: A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected NSCLC	G. Goss
2:20 – 2:25 pm	BR.34: A Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous NSCLC	N. Leigh
2:25 – 2:30 pm	BRC.6 (Lung-MAP – S1400): A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer	N. Leigh

2:30 – 2:35 pm	<u>IND.227:</u> A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma	Q. Chu
2:35 – 2:40 pm	<u>IND.238:</u> A Phase II Study of Durvalumab Retreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity	P. Ellis/ S. Taylor
2:40 – 2:50 pm	<u>IND Committee Update – including:</u> Canadian Profiling and Targeted agent Utilization tRial (CAPTUR). A Phase II Basket Trial (PM.1)	R. Juergens
2:50 – 3:05 pm	<u>Coffee Break</u>	
<u>New Trials</u>		
3:05 – 3:15 pm	<u>BRC.7 (ECOG-ACRIN EA5163) INSIGNA:</u> A Randomized, Phase III Study of First line Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post Progression in Advanced Non-squamous NSCLC with Immunobiomarker SIGNature-driven Analysis	A. Robinson
3:15 – 3:25 pm	<u>BR.36 (CRI-CCTG-0002):</u> A Biomarker-Directed, Open Label, Multi-Centre Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with NSCLC	P. Bradbury (for C. Ho)
3:25 – 3:35 pm	<u>BRC.8:</u> S1827: A Randomized Phase III Trial of MRI Surveillance with or without Prophylactic Cranial Irradiation in SCLC	I. Mohamed (on behalf of the RT WG Chair – TBD)
3:35 – 3:40 pm	<u>IND Concept:</u> Gilteritinib-Panitumumab as a novel <i>EGFR</i> C797S inhibitor	A. Sacher
<u>Reports from Working Groups 3:40 – 3:55 pm</u>		
3:40 – 3:45 pm	Lung CSTB Committee	M. Tsao
3:45 – 3:50 pm	SCLC/Lung Radiation JOINT Subcommittee	P. Ellis/ I. Mohamed (on behalf of the RT WG Chair – TBD)
3:50 – 3:55 pm	Mesothelioma/Thymoma Subcommittee	C. Lee
3:55 – 4:00 pm	Summary and discussion of changes to lung executive and working groups	P. Bradbury